Form 4: Macrogenics Director Scott Koenig Acquires Shares

Director Scott Koenig of Macrogenics Inc. has acquired restricted stock units and stock options, indicating continued investment in the company.

Summary

• Director Scott Koenig acquired 3,750 Restricted Stock Units (RSUs) and 22,000 stock options.
• The RSUs represent a contingent right to receive one share of common stock.
• The RSUs will vest one year after the grant date or the day prior to the next annual meeting, whichever is earlier.
• The stock option has an exercise price of $4.52 and will vest and become exercisable in monthly increments over one year.
• These transactions occurred on May 19, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it indicates a director's continued investment and confidence through the acquisition of equity-based compensation, which is standard practice.

Positives

• Director's acquisition of RSUs and stock options suggests confidence in the company's future prospects.
• The vesting schedule for RSUs and stock options aligns with long-term performance incentives.

Future Outlook

The vesting schedules for the RSUs and stock options imply a forward-looking perspective on the company's value and performance, as these instruments are typically granted to incentivize long-term growth.

Industry Context

StockSavvy.ai notes that insider transactions, such as the acquisition of stock options and RSUs by a director, are common in the biotechnology sector as a means to align executive interests with shareholder value and to attract and retain talent.

Stakeholder Impact

• Shareholders may view the director's acquisition of equity as a positive signal of confidence in the company's future performance.
• Employees may be motivated by the alignment of management's interests with their own through equity-based compensation structures.

Next Steps

• RSUs will vest one year after the grant date or the day prior to the next annual meeting, if earlier.
• Stock options will vest and become exercisable in monthly, cumulative 1/12th increments beginning one month from the grant date.

Key Dates

Keywords

Macrogenics, MGNX, Form 4, Insider Trading, Stock Options, Restricted Stock Units, Director, SEC Filing